Officer and Director Files to Sell $314K in Shares, Continuing Recent Trend
KMTS sits 50% above its 52-week low of $13.25.
Summary
An Officer and Director of Kestra Medical Technologies has filed a Form 144 to sell approximately $314,000 worth of common shares, extending a pattern of recent insider sales.
Key Events · Ownership and Investor Activity · KMTS
-
Proposed Insider Sale
Officer and Director Brian Webster has filed a Form 144 indicating intent to sell 15,000 common shares, with an approximate market value of $314,330.
-
Continuation of Selling Pattern
This filing extends a recent trend of sales by Brian Webster, who has already sold 45,000 shares for gross proceeds of $988,815 over the past three months, as detailed in previous Form 144 filings.
-
Shares from Equity Compensation
The shares intended for sale were acquired on January 21, 2026, through a restricted share issuance as part of the company's equity compensation plan.
Analysis · KMTS · Industrial Applications And Services
This Form 144 filing indicates an Officer and Director's intent to sell a notable amount of shares, extending a pattern of insider sales over the past three months. While the individual transaction is not massive relative to the company's market cap, the consistent selling by a key executive can signal a lack of conviction or a need for liquidity, potentially creating an overhang on the stock.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 29.5% of the 1699 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KMTS was trading at $19.82 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $13.25 to $30.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.